The natural history of severe asthma is complex and poorly understood, and until recently we were unable to effectively predict the progression of the disease. To shed light on this important area, we are delighted to share our latest study […]
Extensive article today in the Swedish newspaper Dagens Nyheter on the increasing burden of fatty liver disease (NAFLD), including an interview with Associate Professor Hannes Hagström, co-creater of the HERALD liver data platform together with Quantify Researchs Emilie […]
Quantify is proud to introduce Zoltán Németh, who will strengthen our Modelling, Access, and Strategy team in Stockholm as Senior Research Analyst. Zoltán holds a degree in Health Economics, Policy, and […]
We are excited to welcome Alexandra Cooper to the Quantify Research team, who will be joining the Real World Evidence and Analytics team in Stockholm as a Research Analyst! With a Master’s degree in public health sciences, epidemiology from the […]
Quantify Research is excited to see you next week at the 39th annual International Society for Pharmacoepidemiology (ICPE) meeting in Halifax! Our CEO Kirk Geale will be there in person to […]
Quantify Research recently joined regulators and industry in the EMA’s Multi-stakeholder workshop on Real World Data (RWD) quality and Real World Evidence (RWE) use.
???? ??????????? ??????? ?? ???? ??????????? ???? ???????. ????? ??????? ???? ???? ???:
⭐ […]
Are you attending #EASLCongress this week? Quantify’s Emilie Toresson Grip is on site and would be happy to connect!
Tomorrow, she will present the poster “Healthcare resource use and costs among patients with primary sclerosing cholangitis in Sweden – a retrospective population-based […]
Studying rare diseases in real-world evidence often comes with challenges, such as lack of disease-specific diagnosis codes and complex definition of relevant endpoints. Over the years, Quantify has faced these challenges on […]
Denmark, through the Danish Medicines Council, will join FINOSE! We at Quantify foresee that this can potentially be a great preparation for both HTA bodies and pharmaceutical manufacturers for the upcoming EU HTA regulation. The addition of Denmark to FINOSE […]